Traws Pharma (NASDAQ:TRAW) Releases Earnings Results, Beats Estimates By $0.18 EPS

Traws Pharma (NASDAQ:TRAW) released its earnings results on Friday. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.18, FiscalAI reports.

Traws Pharma Stock Performance

Shares of TRAW traded down $0.03 on Friday, reaching $0.57. The stock had a trading volume of 76,075 shares, compared to its average volume of 110,422. The firm has a market capitalization of $8.65 million, a price-to-earnings ratio of -0.34 and a beta of 1.57. The company has a 50-day simple moving average of $0.73 and a 200-day simple moving average of $1.37. Traws Pharma has a 12-month low of $0.43 and a 12-month high of $3.27.

Institutional Trading of Traws Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC grew its holdings in Traws Pharma by 41.9% in the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after purchasing an additional 18,213 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of Traws Pharma in the 4th quarter worth approximately $175,000. Boothbay Fund Management LLC bought a new stake in shares of Traws Pharma in the 4th quarter worth approximately $220,000. Ikarian Capital LLC increased its position in Traws Pharma by 2,280.0% during the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock valued at $766,000 after buying an additional 649,649 shares in the last quarter. Finally, State Street Corp bought a new position in Traws Pharma during the 4th quarter valued at approximately $29,000. 7.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Citigroup cut shares of Traws Pharma to a “neutral” rating in a research report on Monday, June 15th. HC Wainwright reissued a “negative” rating and issued a $1.00 price target on shares of Traws Pharma in a report on Thursday, June 18th. Weiss Ratings cut shares of Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. Finally, LADENBURG THALM/SH SH downgraded shares of Traws Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 15th. Three research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Traws Pharma has an average rating of “Reduce” and a consensus target price of $1.00.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.